MediWound (NASDAQ:MDWD – Get Rating)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $23.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 110.43% from the company’s previous close.
MDWD has been the subject of several other research reports. StockNews.com initiated coverage on MediWound in a research note on Thursday. They issued a “hold” rating for the company. Cowen raised their price target on MediWound from $6.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, December 30th. Finally, Maxim Group assumed coverage on MediWound in a report on Thursday, December 22nd. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, MediWound presently has an average rating of “Moderate Buy” and an average target price of $40.40.
MediWound Stock Up 2.6 %
Shares of NASDAQ MDWD opened at $10.93 on Friday. MediWound has a 52 week low of $8.05 and a 52 week high of $17.08. The business has a 50-day simple moving average of $12.69 and a two-hundred day simple moving average of $11.47. The company has a market cap of $63.61 million, a P/E ratio of -2.95 and a beta of 0.98.
Hedge Funds Weigh In On MediWound
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.